ClinicalTrials.gg
CompletedNCT04380753Updated May 6, 2026Results posted

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

A Phase 1 interventional study of AMG 510 in Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation, sponsored by Amgen. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.

02

Conditions studied

  • Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

Keywords

  • AMG510 phase 1
  • Chinese Descent
  • Advanced Solid Tumors
  • KRAS p.G12C Mutation
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects greater than or equal to 18 years old
  • Subject is of Chinese ancestry
  • documented, advanced/ solid tumor with KRAS p.G12C mutation identified

Exclusion criteria

Exclusion Criteria:

  • Active from non-brain tumors.
  • Myocardial infarction within 6 months of study day 1.
  • Gastrointestinal (GI) tract disease causing the inability to take oral medication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Subjects will be enrolled and will receive AMG 510 PO QD.

    Drug: AMG 510

Interventions

  • Subjects will be enrolled and will receive AMG 510 PO QD.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLT)

    DLTs were defined as any of the following adverse events (AEs) where a relationship to sotorasib could not be ruled out. Hematological toxicity * febrile neutropenia * neutropenic infection * grade 4 neutropenia * grade ≥ 3 thrombocytopenia for \> 7 days * grade 3 thrombocytopenia with grade ≥ 2 bleeding * grade 4 thrombocytopenia * grade 4 anemia. Non-hematological toxicity * grade ≥ 4 vomiting or diarrhea * grade 3 diarrhea or grade 3 vomiting lasting more than 3 days despite optimal medical support * grade ≥ 3 nausea for 3 days or more despite optimal medical support * any other grade ≥ 3 adverse event.

    Time frame: Day 1 to Day 21

  2. Number of Participants With Treatment-emergent AEs (TEAEs)

    An AE was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an AE starting on or after first dose of study treatment. Treatment-related TEAEs were any TEAEs considered related to investigational product by the investigator. If relationship was missing, the event was assumed treatment-related. Clinically significant changes from the participant's baseline values in vital signs, 12-lead electrocardiograms, and clinical laboratory safety tests were reported as AEs.

    Time frame: Day 1 until the end of study (or primary data cut-off date for ongoing participants); median [min, max] duration was 5.57 [1.5, 13.7] months

  3. Maximum Observed Plasma Concentration (Cmax) of Sotorasib

    Pharmacokinetic (PK) parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8

  4. Time to Achieve Cmax (Tmax) of Sotorasib

    PK parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8

  5. Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h) of Sotorasib

    PK parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8

Secondary outcomes

  1. Objective Response (OR)

    Measured by computed tomography (CT) or magnetic resonance imaging (MRI). Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines.

    Time frame: Day 1 until the end of study (approximately 12 months)

  2. Duration of Response (DoR)

    Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

    Time frame: Day 1 until the end of study (approximately 12 months)

  3. Progression-free Survival (PFS)

    Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

    Time frame: Day 1 until the end of study (approximately 12 months)

  4. Disease Control Rate (DCR)

    Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

    Time frame: Day 1 until the end of study (approximately 12 months)

  5. Time to Response (TTR)

    Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

    Time frame: Day 1 until the end of study (approximately 12 months)

  6. Duration of Stable Disease

    Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

    Time frame: Day 1 until the end of study (approximately 12 months)

07

Results

Posted Mar 22, 2024

Participant flow

A total of 12 participants were enrolled in the study in Hong Kong and Taiwan. The study is currently ongoing; results are reported up to the primary data cut-off date of 31 December 2021.

Participant flow — Overall Study
MilestoneSotorasib
Started12
Completed6
Not completed6
Withdrew: Participants continuing study4
Withdrew: Death2

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLT)

DLTs were defined as any of the following adverse events (AEs) where a relationship to sotorasib could not be ruled out. Hematological toxicity * febrile neutropenia * neutropenic infection * grade 4 neutropenia * grade ≥ 3 thrombocytopenia for \> 7 days * grade 3 thrombocytopenia with grade ≥ 2 bleeding * grade 4 thrombocytopenia * grade 4 anemia. Non-hematological toxicity * grade ≥ 4 vomiting or diarrhea * grade 3 diarrhea or grade 3 vomiting lasting more than 3 days despite optimal medical support * grade ≥ 3 nausea for 3 days or more despite optimal medical support * any other grade ≥ 3 adverse event.

Time frame:
Day 1 to Day 21
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities (DLT)
ParticipantsSotorasib
Number of Participants With Dose-limiting Toxicities (DLT)0
PrimaryNumber of Participants With Treatment-emergent AEs (TEAEs)

An AE was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an AE starting on or after first dose of study treatment. Treatment-related TEAEs were any TEAEs considered related to investigational product by the investigator. If relationship was missing, the event was assumed treatment-related. Clinically significant changes from the participant's baseline values in vital signs, 12-lead electrocardiograms, and clinical laboratory safety tests were reported as AEs.

Time frame:
Day 1 until the end of study (or primary data cut-off date for ongoing participants); median [min, max] duration was 5.57 [1.5, 13.7] months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent AEs (TEAEs)
ParticipantsSotorasib
Any TEAEs11
Any Treatment-related TEAEs4
PrimaryMaximum Observed Plasma Concentration (Cmax) of Sotorasib

Pharmacokinetic (PK) parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Sotorasib
ng/mLSotorasib
Day 19010 ± 5200
Day 86330 ± 3030
PrimaryTime to Achieve Cmax (Tmax) of Sotorasib

PK parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8
Reported as:
Median · hours
Time to Achieve Cmax (Tmax) of Sotorasib
hoursSotorasib
Day 10.85 (0.50 to 6.00)
Day 80.96 (0.47 to 5.90)
PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h) of Sotorasib

PK parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h) of Sotorasib
hours*ng/mLSotorasib
Day 173200 ± 43700
Day 837400 ± 32000
SecondaryObjective Response (OR)

Measured by computed tomography (CT) or magnetic resonance imaging (MRI). Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines.

Time frame:
Day 1 until the end of study (approximately 12 months)

Results for this outcome have not been posted.

SecondaryDuration of Response (DoR)

Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

Time frame:
Day 1 until the end of study (approximately 12 months)

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS)

Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

Time frame:
Day 1 until the end of study (approximately 12 months)

Results for this outcome have not been posted.

SecondaryDisease Control Rate (DCR)

Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

Time frame:
Day 1 until the end of study (approximately 12 months)

Results for this outcome have not been posted.

SecondaryTime to Response (TTR)

Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

Time frame:
Day 1 until the end of study (approximately 12 months)

Results for this outcome have not been posted.

SecondaryDuration of Stable Disease

Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.

Time frame:
Day 1 until the end of study (approximately 12 months)

Results for this outcome have not been posted.

Adverse events

Collected over Day 1 until the end of study (or primary data cut-off date for ongoing participants); median [min, max] duration was 5.57 [1.5, 13.7] months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotorasib2/12 (16.7%)6/12 (50%)11/12 (91.7%)
Most frequent serious events
Most frequent serious events
EventSotorasib
PneumothoraxRespiratory, thoracic and mediastinal disorders2/12
IleusGastrointestinal disorders1/12
PyrexiaGeneral disorders1/12
PneumoniaInfections and infestations1/12
Liver function test abnormalInvestigations1/12
ArthralgiaMusculoskeletal and connective tissue disorders1/12
Spinal cord compressionNervous system disorders1/12
DyspnoeaRespiratory, thoracic and mediastinal disorders1/12
Most frequent other events
Showing 10 of 44
Most frequent other events
EventSotorasib
ConstipationGastrointestinal disorders3/12
GastritisGastrointestinal disorders2/12
PneumoniaInfections and infestations2/12
HypokalaemiaMetabolism and nutrition disorders2/12
AnaemiaBlood and lymphatic system disorders1/12
TachycardiaCardiac disorders1/12
Adrenal insufficiencyEndocrine disorders1/12
Euthyroid sick syndromeEndocrine disorders1/12
Abdominal distensionGastrointestinal disorders1/12
DiarrhoeaGastrointestinal disorders1/12

Baseline characteristics

Safety analysis set: all enrolled participants who received at least 1 dose of sotorasib.

Age, Continuous
Age, Continuous(years)Sotorasib
Mean64.9 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Sotorasib
Female4
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotorasib
Hispanic or Latino0
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotorasib
American Indian or Alaska Native0
Asian12
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • University of Hong Kong, Queen Mary Hospital
    Hong Kong, Hong Kong
  • Prince of Wales Hospital
    Shatin, New Territories, Hong Kong
  • Veterans General Hospital - Taichung
    Taichung, 40705, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in Dec 2021, 20 months.

Results were first posted in Mar 2024, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 8, 2020
StartActual
Apr 28, 2020
Primary completionActual
Dec 31, 2021
CompletionActual
Feb 9, 2026
Results first posted
Mar 22, 2024
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04380753
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 8, 2020
Start date
Apr 28, 2020
Primary completion
Dec 31, 2021
Completion
Feb 9, 2026
Results posted
Mar 22, 2024
Last update
May 6, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion